A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer
Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, Krop IE, Girish S, Friberg LE, Gupta M. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemotherapy And Pharmacology 2012, 70: 591-601. PMID: 22886072, DOI: 10.1007/s00280-012-1934-7.Peer-Reviewed Original ResearchConceptsT-DM1 3.6Incidence of gradePK/PD modelBaseline characteristicsPlatelet countT-DM1Semimechanistic PK/PD modelHER2-positive metastatic breast cancerPharmacodynamic modelPD modelHuman epidermal growth factor receptorGrade 3 thrombocytopeniaPatient baseline characteristicsPhase II studyDose-limiting toxicityMetastatic breast cancerPatient's platelet countSingle-agent studiesPD parametersEpidermal growth factor receptorAntibody-drug conjugatesGrowth factor receptorDose delaysFirst doseII study